A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Grupo Español de Investigación en Cáncer de Ovario
Seagen Inc.
Merck Sharp & Dohme LLC
GOG Foundation
M.D. Anderson Cancer Center
Shanghai Shengdi Pharmaceutical Co., Ltd
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The Netherlands Cancer Institute
Kortuc, Inc.
CanariaBio Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Uganda Cancer Institute
AstraZeneca
Massachusetts General Hospital
AstraZeneca
Genelux Corporation
Centre Oscar Lambret
Washington University School of Medicine
M.D. Anderson Cancer Center
Qilu Pharmaceutical Co., Ltd.
City of Hope Medical Center
Tata Memorial Hospital
Merck Sharp & Dohme LLC
National Cancer Center, Korea
University of Pittsburgh
Jiangsu Cancer Institute & Hospital
Ohio State University Comprehensive Cancer Center
Institut du Cancer de Montpellier - Val d'Aurelle
Merck Sharp & Dohme LLC